Universe Pharmaceuticals (UPC) Total Non-Current Liabilities (2024)
Universe Pharmaceuticals (UPC) posted Total Non-Current Liabilities of $2.1 billion for Q3 2024, up 9402.37% sequentially from $22.5 million in Q1 2024.
Universe Pharmaceuticals (UPC) Total Non-Current Liabilities (2024) Analysis & Trends
Universe Pharmaceuticals has reported Total Non-Current Liabilities for 1 years, with the latest figure at $2.1 billion in Q3 2024.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $2.1 billion in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2.1 billion (changed N/A YoY) and the FY2024 annual result came in at $2.1 billion, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $2.1 billion in Q3 2024 per UPC's latest filing, from $22.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $2.1 billion in Q3 2024 and troughed at $22.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Universe Pharmaceuticals | 2.93 Mn | -26.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.14 Bn |
| Mar 31, 2024 | 22.49 Mn |